ArticleTranslational andrology and urology2026
Prognostic and immunological implications of a mitophagy-associated gene signature in bladder cancer.
Article in Translational andrology and urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The pronounced heterogeneity of bladder cancer (BLCA) drives divergent patient outcomes and therapy responses. Mitophagy, a pivotal cellular quality-control and metabolic mechanism, modulates the dynamics of the tumor microenvironment (TME). Its prognostic significance and potential for guiding precision oncology, however, remain incompletely defined. This investigation aimed to evaluate the translational utility of mitophagy-associated signatures for the risk stratification of BLCA, profiling of TME, and prediction of therapeutic response. Methods: Using The Cancer Genome Atlas (TCGA)-BLCA cohort, a prognostic signature was established via least absolute shrinkage and selection operator (LASSO) and multivariable Cox regression analyses. The robustness of the signature was externally validated using two independent cohorts from the Gene Expression Omnibus (GSE32894, n=224; GSE31684, n=93). A nomogram was established to estimate survival probability. A multi-faceted analysis of TME features was conducted to compare the subgroups, integrating three algorithms: Cell-Type Identification by Estimating Relative Subsets of RNA Transcripts (CIBERSORT), Tumor Immune Dysfunction and Exclusion (TIDE), and Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data (ESTIMATE). Drug sensitivity and molecular alteration profiles were interrogated to identify potential personalized therapeutic avenues. Results: A five-core-gene signature ( Conclusions: This research developed a mitophagy-derived signature that predicts survival and is associated with a potential 'stromal barrier and immune-excluded' phenotype underlying therapy resistance in high-risk BLCA. The model offers a stratification framework for therapeutic decisions. Standard chemotherapy or immune checkpoint blockade (ICB) may lead to benefits in the low-risk subgroup, whereas high-risk individuals likely require novel combinatorial strategies targeting microenvironmental remodeling. However, as these results represent predictive associations derived from public datasets, further experimental validation is warranted to confirm the underlying biological mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.